IBRX Stock Surges 94% With A 6-day Spree On 700% ANKTIVA Revenue Surge
ImmunityBio (IBRX) – a developer of immunotherapies and vaccines for cancer and infections. – hit a 6-day winning streak, with cumulative gains over this period amounting to 94%. The company’s market cap has surged by about $5.3 Bil over the last 6 days and currently stands at $11 Bil.
The stock has YTD (year-to-date) return of 483.3% compared to 0.7% for S&P 500. This calls for a re-evaluation of the stock’s valuation to find out whether this is an opportunity or a trap.
What Triggered The Rally?
[1] Record 2025 ANKTIVA Sales & Earnings Beat
- Stress Testing AXON: Historical Drawdowns and Macro Risks
- Stress Testing PLTR: Historical Drawdowns and Macro Risks
- The Bear Case: How INTA Behaves During Market Shocks
- The Bear Case: How GTLB Behaves During Market Shocks
- The Bear Case: How NKE Behaves During Market Shocks
- Why Alphabet Stock Jumped 70%?
- 700% YoY Revenue Growth To $113 Million
- Beat Analyst EPS Estimates
- Impact: Sharp Rally Acceleration, Massive Volume Spike
[2] European Commission Marketing Authorization
- First EU-Authorized Immunotherapy For Indication
- Analyst Price Target Hikes to $23
- Impact: Stock Soared 41.9% Post-Announcement, Expanded Market Access to 33 Countries
Opportunity or Trap?
Below is our take on valuation.
There are only a couple of things to fear in IBRX stock given its overall Moderate operating performance and financial condition. But keeping in mind its Very High valuation, we think that the stock is Unattractive (For details, see Buy or Sell IBRX).
But here is the real interesting point.
You are reading about this 94% move after it happened. The market has already priced in the news. To catch the next winner before the headlines, you need predictive signals, not notifications. Our High Quality Portfolio has flagged 5 new opportunities that have not surged yet.
Returns vs S&P 500
The following table summarizes the return for IBRX stock vs. the S&P 500 index over different periods, including the current streak:
| Return Period | IBRX | S&P 500 |
|---|---|---|
| 1D | 17.5% | 0.8% |
| 6D (Current Streak) | 94.3% | 0.8% |
| 1M (21D) | 79.1% | -0.4% |
| 3M (63D) | 471.8% | 5.4% |
| YTD 2026 | 483.3% | 0.7% |
| 2025 | -22.7% | 16.4% |
| 2024 | -49.0% | 23.3% |
| 2023 | -1.0% | 24.2% |
However, big gains can follow sharp reversals – but how has IBRX behaved after prior drops? See IBRX Dip Buyer Analysis to learn more.
Gains and Losses Streaks: S&P 500 Constituents
There are currently 70 S&P constituents with 3 days or more of consecutive gains and 27 constituents with 3 days or more of consecutive losses.
| Consecutive Days | # of Gainers | # of Losers |
|---|---|---|
| 3D | 33 | 14 |
| 4D | 26 | 10 |
| 5D | 7 | 2 |
| 6D | 0 | 1 |
| 7D or more | 4 | 0 |
| Total >=3 D | 70 | 27 |
Key Financials for ImmunityBio (IBRX)
Last 2 Fiscal Years:
| Metric | FY2023 | FY2024 |
|---|---|---|
| Revenues | $0.6 Mil | $14.7 Mil |
| Operating Income | $-361.4 Mil | $-344.2 Mil |
| Net Income | $-583.2 Mil | $-413.6 Mil |
Last 2 Fiscal Quarters:
| Metric | 2025 FQ2 | 2025 FQ3 |
|---|---|---|
| Revenues | $26.4 Mil | $32.1 Mil |
| Operating Income | $-71.3 Mil | $-55.6 Mil |
| Net Income | $-92.6 Mil | $-67.3 Mil |
While IBRX stock looks attractive given its winning streak, investing in a single stock without detailed, thorough analysis can be risky. The Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming its benchmark that includes all 3 — the S&P 500, S&P mid-cap, and Russell 2000 indices. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.